# Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

> **NCT07327489** · — · RECRUITING · sponsor: **Elephas** · enrollment: 2000 (estimated)

## Conditions studied

- Cancer
- Immunotherapy
- Advanced Solid Tumors Cancer
- Bladder Cancer
- TNBC, Triple Negative Breast Cancer
- Colorectal Cancer
- DMMR Colorectal Cancer
- MSI-H Colorectal Cancer
- Endometrial Cancer
- Head and Neck Cancer
- Kidney Cancer
- Liver Cancer
- NSCLC (Non-small-cell Lung Cancer)
- Skin Cancer
- Melanoma (Skin Cancer)

## Interventions

- **PROCEDURE:** Biopsy

## Key facts

- **NCT ID:** NCT07327489
- **Lead sponsor:** Elephas
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-14
- **Primary completion:** 2035-04
- **Final completion:** 2038-04
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07327489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07327489, "Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07327489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*